



A Scoping Review of the Pharmacovigilance Systems in West African region

Jalloh, Isatu; James, Peter Bai; Abiri, Onome Thomas; Wiafe, Ebenezer; et al.

<https://researchportal.scu.edu.au/esploro/outputs/journalArticle/A-Scoping-Review-of-the-Pharmacovigilance/991013309993002368/filesAndLinks?index=0>

Jalloh, I., James, P. B., Abiri, O. T., Wiafe, E., Mensah, K., & Padayachee, N. (2025). A Scoping Review of the Pharmacovigilance Systems in West African region. *Christian Journal for Global Health*, 12(2), 33–59.

<https://doi.org/10.15566/cjgh.v12i2.419>

Document Version: Published (Version of record)

Published Version: <https://doi.org/10.15566/cjgh.v12i2.419>

Southern Cross University Cross Connect: <https://researchportal.scu.edu.au/esploro/crossconnect@scu.edu.au>

CC BY V4.0

Research:Open

© 2025 The author(s).

Downloaded On 2025/09/18 14:56:07 +1000



A scoping review of the pharmacovigilance systems in west African region

Isatu Jalloh^a, Peter Bai James^b, Onome Thomas Abiri^c, Ebenezer Wiafe^d, Kofi Mensah^e, Neelaveni Padayachee^f

^a PhD Candidate, Department of Pharmacy and Pharmacology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Associate lecturer Department of Clinical Pharmacy and Therapeutics, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone

^b PhD, Lecturer, Course Coordinator & Research Fellow, National Centre for Naturopathic Medicine, Faculty of Health, Southern Cross University, Lismore, Australia. Faculty of Pharmaceutical Sciences, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone

^c Department of Pharmacology and Therapeutics, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone; Department of Pharmacovigilance and Clinical Trials, Pharmacy Board of Sierra Leone, Freetown, Sierra Leone

^d PhD, Department of Pharmacy Practice, School of Pharmacy, University of Health and Allied Sciences, Ho, Ghana. Discipline of Pharmaceutical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa. Directorate of Pharmacy, Ho Teaching Hospital, Ho, Ghana

^e Department of Pharmacy Practice, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana

^f PhD, Associate professor Department of Pharmacy and Pharmacology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

Abstract

Background: Pharmacovigilance is essential for monitoring drug safety and managing adverse drug reactions, particularly in the context of increasing medication use in West Africa. This review aims to assess the existing state of pharmacovigilance systems, regulatory frameworks, and adverse drug reaction reporting practices across the West African region.

Methods: A systematic scoping review was performed in accordance with the methodology set out by the Joanna Briggs Institute, adhering to the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews) guidelines. Literature searches conducted across seven databases resulted in 3,000 documents, of which 59 studies met the inclusion criteria. The included studies originated from six countries: Ghana, Nigeria, Burkina Faso, Côte d'Ivoire, Sierra Leone, and Senegal. Key themes identified in the review encompass pharmacovigilance systems, related policies, collaboration among stakeholders, and the challenges associated with reporting adverse drug reactions.

Results: While all West African countries have established national pharmacovigilance centers and WHO Collaborating Center membership, gaps persist in legislation, enforcement, and public awareness. Challenges include inadequate resources, limited healthcare professional training, and communication barriers. Recommendations emphasize education, stakeholder engagement, and public awareness to improve adverse drug reaction reporting.

Conclusion: Strengthening pharmacovigilance in West Africa requires a multi-pronged approach prioritizing policy, collaboration, and education to ensure drug safety and public health.

Keywords: Pharmacovigilance, Adverse Drug Reactions, West Africa, Healthcare Professionals, Regulatory Frameworks, Stakeholder Collaboration, Public Awareness.

Introduction

Pharmacovigilance, as defined by the World Health Organization (WHO) is “the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems.”¹ It is a critical component of the global healthcare systems. It ensures drug safety by continuously monitoring medications, identifying risks, and implementing measures to minimize harm throughout a drug’s lifecycle.²⁻⁶ Pharmacovigilance systems aim to safeguard public health by addressing adverse drug reactions (ADRs), a significant cause of morbidity, mortality, and financial strain on healthcare systems worldwide.⁷⁻¹⁰ Globally, pharmacovigilance evolved in response to significant drug safety crises, notably the thalidomide tragedy of the 1960s. The incident underscored the inadequacy of existing drug monitoring frameworks, catalyzing the WHO Programme for International Drug Monitoring (PIDM) establishment and creating the Uppsala Monitoring Centre (UMC) to manage global ADRs reporting through VigiBase.¹¹ Today, pharmacovigilance encompasses many functions, including data collection, signal detection, risk communication, and regulatory interventions to ensure public trust and safety.^{4,12}

The significance of pharmacovigilance is amplified in regions like West Africa, where healthcare systems are often strained by resource limitations, insufficient infrastructure, and underdeveloped regulatory frameworks.^{4,13,14} ^{15,16} The rapid introduction of new medicines and vaccines, particularly in response to emerging diseases, highlights the critical need for robust pharmacovigilance systems. Effective

pharmacovigilance can identify, assess, and mitigate ADRs, ensuring that medications provide their intended therapeutic benefits while minimizing risks.¹⁷⁻¹⁹ Despite advancements, deficiencies still need to be improved in the pharmacovigilance systems of West Africa. Numerous nations have created national pharmacovigilance centers and are affiliated with WHO’s Programme for International Drug Monitoring.^{2,11,20} Nonetheless, obstacles such as inadequate healthcare professional training, a deficient ADRs reporting culture, and communication difficulties impede the efficacy of these systems.²⁰⁻²⁵ Regulatory frameworks and public awareness programs remain underdeveloped, exacerbating underreporting of ADRs—a problem compounded by cultural and systemic factors.^{23,26,27}

This scoping review aims to systematically assess and map the pharmacovigilance systems and adverse drug reaction (ADR) reporting practices across West African nations. It will examine various aspects, including regulatory frameworks, stakeholder engagement, and operational challenges. The review will encompass the following countries: Benin, Burkina Faso, Cape Verde, Côte d’Ivoire, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Niger, Nigeria, Senegal, Sierra Leone, and Togo. By identifying gaps and highlighting advancements, this review seeks to offer actionable recommendations for improving pharmacovigilance systems within the region. Such efforts are crucial for ensuring that West Africa aligns with global pharmacovigilance standards, fortifies healthcare systems, and enhances patient safety.

Method

This scoping review followed the Joanna Briggs Institute (JBI) methodology and adhered to the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews) guidelines.²⁸ The primary aim was to map the literature on pharmacovigilance systems and ADRs reporting in West Africa, identifying advancements, challenges, and opportunities for improvement.

Search Strategy

A comprehensive search strategy was developed with one of the Witwatersrand College of Health Sciences Librarian to ensure inclusivity and rigor. The search included relevant terms such as “*pharmacovigilance systems*,” “*adverse drug reaction reporting*,” and “*West Africa*,” combined using Boolean operators and Medical Subject Headings (MeSH). The databases searched included PubMed, Scopus, Web of Science, MEDLINE, EMBASE, CINAHL Plus, and Google Scholar.

The search was conducted between April 17 and April 30, 2024, and included studies published from January 1, 2001, to April 2024. This timeframe was selected because Ghana became the first West African country to join the WHO Programme for International Drug Monitoring in 2001.^{29,30} Additional grey literature was identified through manual searches of institutional repositories and reference lists of included studies.

Inclusion and Exclusion Criteria

Inclusion Criteria:

- Studies published between 2001 and 2024.
- Focus on pharmacovigilance and ADRs reporting in West African countries.
- Articles discussing pharmacovigilance systems, frameworks, challenges, and stakeholder roles.
- English-language publications.
- Studies involving human participants.

Exclusion Criteria:

- Studies published outside the timeframe.
- Commentaries, editorials, and animal studies.

Study Selection

EndNote version 20 was employed to import the search results and eliminate duplicate entries. The screening process was conducted in two stages:

1. **Title/Abstract Screening:** Articles were assessed for relevance based on their titles and abstracts.
2. **Full-Text Screening:** Articles meeting the initial criteria were subjected to a detailed evaluation in accordance with the established inclusion criteria.

The selection process was carried out by two independent reviewers. Any discrepancies between the reviewers were addressed through discussion, and co-authors were consulted as necessary to reach a consensus on the articles to be included in the final review. Throughout this procedure, the study selection methodology was meticulously documented and visualized using a PRISMA flow diagram.

Data Extraction

A standardized data extraction form was developed to ensure consistency. Key variables included:

- **Study Characteristics:** Author, title, year, country.
- **Pharmacovigilance Features:** Frameworks, ADRs reporting tools, and WHO program collaborations.
- **Outcomes and Recommendations:** Challenges, successes, and proposed solutions.
- **Themes Identified:** Stakeholder involvement, gaps, and recommendations for improving pharmacovigilance systems.

Data extraction was performed by one reviewer and cross-validated by another to minimize errors and ensure completeness.

Data Analysis and Presentation

Extracted data were analyzed using a descriptive statistical approach and thematic coding.

1. Descriptive Statistical Analysis:

- Quantitative data were summarized, including the distribution of studies by country, publication year, and study design.

2. Data Categorization and Thematic Coding:

- Data were systematically categorized into predefined themes:
 - National Pharmacovigilance Systems
 - ADRs Reporting Mechanisms
 - Stakeholder Involvement
 - Challenges and Barriers
 - Recommendations and Best Practices
- Thematic analysis identified recurring patterns and insights aligned with the study objectives.

3. Presentation:

- The findings were presented in a narrative synthesis, supported by visual representations (e.g., tables and figures) to ensure clarity and accessibility.

Quality Appraisal and Risk of Bias

In line with JBI guidelines, a formal quality appraisal and risk of bias assessment was not conducted, as this is not typically required for scoping reviews. The focus remained on mapping the available literature to identify knowledge gaps and thematic insights.


Ethics

Ethical approval was not required as the review relied solely on publicly available literature. All procedures adhered to ethical standards for conducting systematic and scoping reviews.

Results

The systematic search identified a total of 3,000 documents. After removing 1,054 duplicates, 1,946 articles were screened by title and abstract. Subsequently, 89 studies were chosen for comprehensive examinations, of which 59 satisfied the inclusion criteria and were incorporated into the final analysis (Figure 1). A detailed presentation of these studies is shown in Table 1 and summary of the findings per country in Table 2.

Figure 1. PRISMA flow diagram for selection criteria for Pharmacovigilance and ADRs reporting in West Africa.



Characteristics of Included Studies

The 59 included studies spanned across six West African countries: Ghana (17 studies), Nigeria (36 studies), Burkina Faso (2 studies), Côte d'Ivoire (2 studies), Sierra Leone (1 study), and Senegal (1 study). This distribution highlights a concentration of pharmacovigilance research

in Nigeria and Ghana, while studies from other countries remain limited (table 1, 2 and figure 2). The included studies comprised: cross-sectional studies ($n = 22$), qualitative studies ($n = 10$), mixed-methods studies ($n = 15$), and National reports and guidelines ($n = 12$). This information is shown in Table 1, below.

Figure 2. A map highlighting the pharmacovigilance system strengths across the 16 countries in West Africa.




Table 1. Characteristics of included studies

Reference	Country	Study design	Pharmacovigilance systems level	Collaboration with WHO program	National Database	Outcome/Themes	Recommendation
Abiri et al. 201920	Sierra Leone	Cross sectional study	Established basic structures for pharmacovigilance activities, formal organizational structure, medicine safety advisory committee, national pharmacovigilance guideline,	Joined the WHO Collaborating Centre for International Drug Monitoring in 2008. 87th member and is a full member.	Established in 2008, contains reports from clinical trials, immunization programmes and health facilities		Pharmacovigilance legislation for medicine safety monitoring. Incorporate active surveillance activities into the pharmacovigilance system. Collaborate with research institutions, universities, professional regulatory associations and healthcare programs Pharmacovigilance to be included in curriculum health related courses.
Aborigo et al. 202231	Ghana	Descriptive in-depth interviews	Adverse effects following immunization (AEFI) reports flow from the healthcare professional to the district disease control officers, to the regional coordinators and then to the national and finally to the FDA.	Expanded Program on Immunization collaborates with WHO for AEFIs surveillance	Database maintained at both district and regional offices, reports are submitted to the national Expanded programme for immunization (EPI) office and then to the FDA.	Reasons for under-reporting are lack of knowledge, workload, lack of motivation, fear of blame and cost of reporting. Reporting can be improved by Capacity building, simplified and standardized reporting systems, supportive supervision and incentivizing reporting.	To explore the use of electronic reporting to increase AEFI reporting in Ghana.
Acheampong et al. 201532	Ghana	Retrospective review and key informant interviews				Attitude of healthcare professionals, lack of knowledge, communication barriers and workload	Pharmacists to improve their clinical knowledge to be accepted as partners in the management team
Adedeji et al. 202133	Nigeria	Cross-sectional survey (self-administered questionnaire)				Have a positive attitude. Inadequate knowledge and training, poor ADRs reporting, lack of information on ADRs in primary health Care (PHC) facilities, trained community health extension workers are more likely to report an observed ADR. Males more likely to report ADRs than females.	Training interventions on ADRs reporting urgently needed

Reference	Country	Study design	Pharmacovigilance systems level	Collaboration with WHO program	National Database	Outcome/Themes	Recommendation
Adegbuyi et al. 202134	Nigeria	Self-administered questionnaire-based study	Healthcare professionals document the observed or reported ADR on the yellow card. The report is then submitted to the hospital pharmacovigilance committee and then to the regional pharmacovigilance center. Reports are collated and analyzed by the National Pharmacovigilance Centre and then submitted to WHO global	Collaborate with WHO and submit collated reports of ADRs to WHO Global.	The National Pharmacovigilance Centre collates, and analyses reports from all the regional pharmacovigilance centers in the country.	Healthcare professionals have positive attitudes. Pharmacists are highly knowledgeable. High pharmacovigilance knowledge tertiary level facilities. Healthcare professionals preferred internet/web reporting to paper base forms or telephonic /text messages. Reasons for not reporting include lack of time and compensation. Lack of knowledge, no action taken after reporting	Incentivizing ADR reporting. Building capacity for frontline workers. Simplified reporting methods
Adisa et al .201935	Nigeria	Questionnaire-guided interview	Nigeria implemented a mobile phone alert system, the Pharmacovigilance Rapid Alert System for Consumer Reporting (PRASCOR) in 2012 to enable the public to report suspected ADRs directly to NPC			Learned about pharmacovigilance through the news (television and radio) and social media. Pharmacist's counselling does not cover ADRs. Good knowledge of the concept of serious ADRs. Majority believed that reporting ADRs is necessary to prevent harm.	Educating stakeholders on pharmacovigilance. Disseminating the PRASCOR initiative to the public
Kukula et al. 201536	Ghana	Prospective, observational, cohort study				Use of Mobile phones in reporting is effective and affordable	ADRs events to be monitored through phone calls in resource constraint settings
Adisa et al. 201937	Nigeria	Questionnaire-guided survey				Healthcare professionals have awareness, lack knowledge and a moderately positive attitude towards reporting. Patients have low awareness. Challenges in ADR reporting include unavailability of form, lack of expertise in the ADR form.	Continuous training on pharmacovigilance mandatory. Public awareness campaigns on spontaneous ADR reporting



Reference	Country	Study design	Pharmacovigilance systems level	Collaboration with WHO program	National Database	Outcome/Themes	Recommendation
Adu-Gyamfi et al. 202238	Ghana	Cross-sectional study (self-administered structured questionnaire)		Joined WHO Programme for International Drug monitoring and started pharmacovigilance and spontaneous ADR monitoring activities in 2001		Lack knowledge of pharmacovigilance. ADR was not reported due to workload, lack of knowledge and unavailability of reporting forms.	Reporting forms are accessible, integrating electronic reporting, giving feedback for reporting
Agu et al. 201239	Nigeria	Cross-sectional study,				Counselling and education on ADR contributed to positive attitude and drug compliance	
Anyachebelu et al. 201840	Nigeria	Mixed method (questionnaire, observation and interviews)				Good knowledge, poor compliance and poor reporting	Design Pharmacovigilance programs for pharmacists to improve the ADR reporting process.
Appiah et al. 201941	Ghana	Interviews and focus group discussion				Most patients stop the medications when they experience ADRs and do not report because of lack of knowledge	Mobile phone caller tunes can be used to educate the public on ADRs and drug safety
Asiamah et al. 202242	Ghana	A questionnaire-based cross-sectional study	Institutional Contact Persons at facilities that serve as the link between the FDA and the health professionals for ADR reporting. Mandatory ADR reporting by Pharmaceutical Manufacturing Companies. Manufacturing Companies have Qualified Person for Pharmacovigilance to report ADR and pharmacovigilance for all the products and to FDA	Joined the International Medicine Safety Monitoring System in 2001 as the 65th Member State and the 1st in sub-Saharan Africa	Ghana FDA keeps an ADR data repository	Average knowledge and low ADR reporting.	Awareness campaigns through media sensitization and stakeholders' engagement on the need to report all ADRs. A policy on mandatory reporting to be implemented

Reference	Country	Study design	Pharmacovigilance systems level	Collaboration with WHO program	National Database	Outcome/Themes	Recommendation
Avong et al. 201843	Nigeria	A Structured Pharmacovigilance and Training Initiative (SPHAR-TI) model was used	The NAFDAC has a National Pharmacovigilance Policy and an administrative structure represented in Abuja and Centers in all the six geographic regions.	Nigeria joined the International Drug Monitoring Scheme in 2004 and became the 74th member country	All reports are submitted to NPC, reports are validated and analyses and then submitted into Vigibase	Form is the primary tool for reporting. The SPHAR-TI model designed for capacity building to improve reporting and ADR reporting increased. Activation of Pharmacovigilance Committees at facility levels	
Awodele et al. 201244	Nigeria	descriptive cross-sectional survey				Patent medicine vendors (PMVs) play a crucial role in pharmacovigilance activity. The bulk of the PMVs have above secondary school education. ADRs not reported for fear of prosecution. Training significantly improved knowledge, attitude and reporting	NPC to make Rereporting forms accessible. Patients in the rural areas can report to nearby PMVs stores where there are no nearby health facilities.
Awodele et al. 201145	Nigeria	cross sectional descriptive survey				Good knowledge of pharmacovigilance. Reasons for not reporting are lack of access to forms and fear of prosecution. Training is needed for doctors in the private health sector. Public sensitization to report all ADRs to their health care professionals	Inclusion of pharmacovigilance in both undergraduate and post-graduate medical school curriculum.
Awodele et al. 201346	Nigeria	cross sectional descriptive survey	As per WHO guidelines all herbal medicines are expected to have adverse effects and as pharmacovigilance systems urges all members to be aware of this fact			Public awareness efforts on pharmacovigilance. Pharmacovigilance of herbal medicines not monitored. Herbal medicines to go through quality assurance testing. Reporting of ADRs due to herbal medicines to the pharmacovigilance center.	Support direct consumer report to improve ADRs from herbal medicines. Adverse effects herbal medicines to be incorporated into the pharmacovigilance systems.
Balogun et al. 201447	Nigeria	Cross-sectional survey study				Reporting high. Strengthening patient participation in pharmacovigilance of HAART. Educate patients on reporting all suspected ADRs early	

Reference	Country	Study design	Pharmacovigilance systems level	Collaboration with WHO program	National Database	Outcome/Themes	Recommendation
Balogun et al. 2021 ⁴⁸	Nigeria	WHO data collection form for pharmacovigilance indicators	Pharmacovigilance system has components of adequate for safety monitoring of herbal medicines use.			Pharmacovigilance system is highly limited for the safety monitoring of herbal medicines .	Improvement needed on active surveillance of efficacy and safety, and causality assessment of HMs-related reports of herbal medicines. Incorporation of Pharmacovigilance into national educational curricula. Awareness campaign and education of the public and relevant professionals on the need to report adverse reactions due to herbal medicines
Bello et al. 2011 ⁴⁹	Nigeria	Self-administered questionnaire-based study				Lack of awareness of ADR and poor reporting. Female physicians prefer not to engage the key actors of pharmaceutical companies on ADRs.	Educational strategies for improving ADR reporting are needed for both patients and physicians.
Chatio et al. 2016 ⁵⁰	Ghana	In-depth interviews				ADRs not reported due to lack of education, patients attitude behavior of healthcare professional. Healthcare professionals to educate and encourage patients to report all reactions immediately	Continued educational training to be integrated into the day-to-day health care services. Encourage ADR reporting. Proper care should be provided for patients experiencing side effects.
Daniel et al. 2021 ⁵¹	Nigeria	Cross-sectional descriptive study				Good knowledge of ADR reporting. Reports from nurses and midwives are low overall. Lack of access to the reporting form.	Training and access to online reporting portal Healthcare professionals to improve ADR reporting
Eze et al. 2023 ⁵²	Nigeria	Cross-sectional study				Improved awareness of pharmacovigilance and ADR reporting. Perceptions of pharmacovigilance and ADR reporting are low. Perception toward ADR reporting is linked to exposure.	Adequate exposure and training for all interns on pharmacovigilance and ADR reporting, possibly making it mandatory.
Ejekam et al. 2020 ¹⁶	Nigeria	Cross-sectional mixed method study		WHO pharmacovigilance Indicators used to assess pharmacovigilance in public health programmes in Nigeria	HIV/AIDS program contributes greatly to ADR reports to the country's database.	ADR reports not included in the annual reports. Poor recording and reporting of ADRs. Insufficient budget allocated for pharmacovigilance activities. Poor internet access, inadequate human resources. Delay in data entry into database.	Update the current ADR form to include therapeutic ineffectiveness and medication error. Pharmacovigilance policy objectives to be included in the academic curriculum



Reference	Country	Study design	Pharmacovigilance systems level	Collaboration with WHO program	National Database	Outcome/Themes	Recommendation
Fadare et al. 2011 ⁵³	Nigeria	Cross-sectional questionnaire-based study	AEFI monitored by the FDA and the Expanded Programme on Immunization with close collaboration with the African Collaborating Centre for Pharmacovigilance (ACC)		National electronic data system for AEFI reporting started in 2002	Healthcare professionals unaware of the availability of pharmacovigilance committee. The use of the Yellow Card for reporting is low. Inclusion of nurses in pharmacovigilance activities will improve ADR reporting	Regular training on and strengthening ADR reporting guidelines among healthcare professionals is needed
Gidudu et al. 2020 ⁵⁴	Ghana.	Cross-sectional survey				lack of knowledge and training, fear of consequences, lack of feedback on the report	Clear policy protecting healthcare professionals needed, supportive supervision, feedback on reports, and adequate training.
Gulma 2023 ⁵⁵	Nigeria	Document review and key informant interviews				Lack of knowledge and poor reporting of ADRs. Reporting is complicated, workload, reactions not severe or life-threatening, unavailability of forms. Actions taken by PHC staff for ADRs cases are, refer the patient, treat the symptoms of the ADR with another drug or counsel the patient and allow the reaction to resolve on its own	
Jaquet et al. 2013 ⁵⁶	Cote d'Ivoire.	Cross-sectional survey study (questionnaire to ART prescribers and a retrospective ADR survey of the medical charts)		Joined WHO program for international drug monitoring as an associate member in 2007		Lack of knowledge and Under reporting of ADRs. Training in pharmacovigilance and ADR monitoring of HIV-infected patients is needed. The use of treatment modification for ADRs monitoring is feasible	
Kabore et al. 2013 ⁵⁷	Burkina Faso	Descriptive cross-sectional study	The pharmacovigilance system was launched in 2008 by the drug regulatory authority of the Ministry of Health (MoH)	Member of the WHO Uppsala Monitoring Centre		National guidelines and standardized operating procedure are limited. No specific legislation on pharmacovigilance. Basic pharmacovigilance resources are in place.	Develop pharmacovigilance legislation, improve stakeholders' coordination. Need for training and supervision. Provide feedback and decentralize pharmacovigilance services. Risk management and communication endeavors should be displayed



Reference	Country	Study design	Pharmacovigilance systems level	Collaboration with WHO program	National Database	Outcome/Themes	Recommendation
Mendoza et al. 2024 ¹²	Côte d'Ivoire	Training and mentoring of healthcare professionals	Pharmacovigilance activities were launched in 1988, and the policy was adopted in April 2014. Pharmacovigilance projects were built on a partnership between GlaxoSmithKline (GSK), PATH, and the Ministry of Health, national health authority, and the national pharmacovigilance center	Joined the WHO Programme for International Drug Monitoring in 2010 (full member)	Have an established database	Training and mentoring healthcare professionals to be incorporated in the standard functioning of health facilities to improve reporting. Acknowledge and provide feedback mechanisms to motivate healthcare professionals Collaboration between public health programmes and the national pharmacovigilance unit to confirm all adverse effects are compiled at the central level, to adequately monitor the safety of medicines.	Use electronic tools compatible with Vigibase to allow prompt AE reporting and faster safety signal detection.
Mohammed et al. 2018 ⁵⁸	Nigeria	Descriptive cross-sectional survey				Good knowledge, perception and attitude towards reporting. Nonavailability of reporting forms. Promotion of continuous medical education.	On the job training for optimal exposure leads to better performance and inculcation of ethical values.
Mohammed et al. 2019 ⁵⁹	Nigeria	Cross sectional survey study				Lack of knowledge. Positive perception of ADRs reporting among traditional medicine practitioners.	Support training of the traditional medicine practitioners on identification and reporting ADRs.
Ndiaye et al. 2018 ⁶⁰	Senegal	Evaluation of reporting using reporting form, mobile phones and active follow-up				Community health professionals to be trained to identify and report adverse effects. Healthcare professionals to be trained in the use of mobile phones to report to improve timely ADRs notification and enhance safety. Supervision of healthcare professionals and community sensitization. Central team to process reports and provide feedback	
Obieze et al. 2022 ⁶¹	Nigeria	cross-sectional survey study				Knowledge, attitude, and practice of pharmaceutical supply chain management leaders can be improved through dissemination of the national pharmacovigilance policy and training. Communication of medicines safety outcomes to the supply chain management could enhance the knowledge attitude and practice of pharmacovigilance.	



Reference	Country	Study design	Pharmacovigilance systems level	Collaboration with WHO program	National Database	Outcome/Themes	Recommendation
Ohajiu-Obodo et al. 2010 ⁶²	Nigeria	cross-sectional survey study				Lack of knowledge, awareness and attitude, under reporting of ADRs. Reasons for not reporting are lack of awareness, lack of commitment by regulatory authorities, poor reporting protocol and unavailability of forms.	
Okezie et al. 2008 ⁶³	Nigeria	cross-sectional survey				Low reporting. Reporting to be included in all specialty meetings. Use of notes and posters on ADRs reporting in all wards and clinics. The pharmacovigilance unit should give regular feedback to doctors to motivate reporting.	
Omoleke et al. 2022 ⁶⁴	Nigeria	In-depth interviews and observations				Healthcare professionals Knowledge is poor. Error during vaccination is most common cause of AEFL. Low uptake of immunization due to AEFL.	Polymakers must consider regular update training for healthcare providers on AEFL.
Opadeyi et al. 2018 ¹⁵	Nigeria	Cross-sectional descriptive survey	Pharmacovigilance policy document introduced in 2012. Creation of zonal centers to decentralize the activities of the National Pharmacovigilance Centre (NPC).	WHO indicators ideal for the evaluation of tertiary Hospitals and help in improving patient safety through Pharmacovigilance. Maps out relevant areas for interventions and alterations in the health information system management		Poor record keeping and lack of data in hospitals. Poor budget allocation for pharmacovigilance. Improvement in medical record documentation. Hospitals with established committees and committed personnel had better reports.	Increased institutionalization of pharmacovigilance may be the first steps to improve pharmacovigilance activities in the tertiary hospitals.
Opadeyi et al. 2019 ⁶⁵	Nigeria	Cross-sectional study				SMS reminders to report ADRs are very useful. Educational intervention leads to Improvement in the knowledge and practice of pharmacovigilance. Regionalization of reporting centers improves reporting	
Oppong et al. 2022 ⁶⁶	Ghana	Cross-sectional study				Treatment failure is often experienced with generic antimicrobials than with branded products. Antibiotics must be stored as per the manufacturer's specification. Suspected ADRs mostly reported to seniors as opposed to completing the form. Training in the documentation of ADRs in the approved form is needed.	

Reference	Country	Study design	Pharmacovigilance systems level	Collaboration with WHO program	National Database	Outcome/Themes	Recommendation
Oreagba et al. 2011 ⁶⁷	Nigeria	Cross-sectional observational survey		Nigeria became a full member as the 74th member country in September 2004.		Lack of knowledge, practice and reporting rate. Reasons for poor reporting include lack of awareness and incentive about pharmacovigilance.	Urgent need for Training in pharmacovigilance and ADR reporting. Inclusion of Pharmacovigilance and ADRs in the curriculum. The basic duties of pharmacists constitute ADR reporting
Osakwe et al. 2013 ⁶⁸	Nigeria	Cross sectional study				Training improved knowledge and practice of pharmacovigilance amongst health care providers. Training sessions should emphasize real life situations and role plays rather than teaching session to make it impactful and long lasting.	Strengthening awareness raising and improvements in pharmacovigilance training methods are essential to enhance the effectiveness of the program.
Osei et al. 2016 ⁶⁹	Ghana	Cross-sectional survey				Failure of reporting ADR is due to the unavailability of forms and lack of knowledge. Acknowledgment letter for report submitted to encourage continued reporting. ADR reporting was made mandatory to improve reporting rates. Professional development and training on pharmacovigilance is an effective strategy to improve ADR reporting	ADR reporting forms to be readily available in all community pharmacies. NPC should consider ways of improving reporting ADRs, for example using social media and direct online reporting.
Osemene et al 2017 ⁷⁰	Nigeria	Cross-sectional survey				Lack of knowledge but positive perceptions towards reporting. Regular curriculum review and expansion of the course content to improve the knowledge in pharmacovigilance. Lay emphasizes hands-on training and focuses on early postgraduate clinical programmes as they accord the students the requisite exposure to real time experiences with patients. Students believed monetary incentives will improve ADR reporting.	
Osemene et al. 2012 ⁷¹	Nigeria	Survey questionnaire				Involvement in the monitoring and reporting of ADRs is very low. Herbal medicines could be toxic. Regular knowledge update through active participation in workshops in pharmacovigilance.	



Reference	Country	Study design	Pharmacovigilance systems level	Collaboration with WHO program	National Database	Outcome/Themes	Recommendation
Oshikoya et al. 2009 ⁷²	Nigeria	Cross-sectional study				Gaps between knowledge and ADRs reporting. Training in pharmacovigilance.	Attitudinal and cultural changes are needed for improvement in reporting. reporting to be an integral part of the clinical activities. More awareness on the reporting form
Oshikoya et al. 2009 ⁷³	Nigeria	Structured questionnaire				Inadequate undergraduate teaching. ADRs prevention is not taught. ADRs reporting to the NPC is low. ADRs prevention, monitoring and reporting form part of the core curriculum of undergraduate CPT teaching.	
Oshikoya et al. 2009 ⁷⁴	Nigeria	Questionnaire survey				Parental reporting of suspected ADRs is feasible. Involve parents in ADR detection and reporting to prevent the occurrence of ADRs. Parental reporting can identify unusual ADRs previously undetected during the initial evaluation of a medicine	
Powell et al. 2023 ⁷⁵	Ghana	Cross-sectional survey				Lack of knowledge and reporting. Designated contact persons for pharmacovigilance in health facilities. Use of mobile phone for ADRs reporting	Regular and sustained engagement with healthcare professionals
Rouamba et al. 2020 ⁷⁶	Burkina Faso	Prospective observational study				Both systems of surveillance (active and passive) are useful. In the passive surveillance system, we noted a relative underreporting of ADRs. Spontaneous reporting is feasible. The active surveillance is achievable but expensive. The Health and Demographic Surveillance System platform is a useful tool for the national pharmacovigilance system to monitor the safety of medicines in rural areas.	
Sabblah et al. 2014 ⁷⁷	Ghana	Cross sectional survey				Training improved ADR reporting. Most doctors had not been trained. Reporting forms to be available. Training and update courses on ADR reporting are to be organized. Acknowledgement and actions taken to be provided for reporters.	
Sabblah et al. 2019 ⁷⁸	Ghana	Cross-sectional study				Feedback provided to all healthcare professionals reported in the form of personalized letters. Patients expect feedback for ADR reports submitted to the NPC. Feedback expected through mobile phones, short messaging services and email.	NPC to explore alternative ways of providing feedback to patients reporting ADRs.

Reference	Country	Study design	Pharmacovigilance systems level	Collaboration with WHO program	National Database	Outcome/Themes	Recommendation
Sabblah et al. 2017 ⁷⁹	Ghana	Cross-sectional survey				Positive attitude and good knowledge of ADR reporting to the NPC. Report because they expect to contribute to drug safety. Patients' decisions to report are influenced by healthcare professionals and family members, and the ease of reporting	Public awareness campaigns and timely feedback of the actions taken to reporting patients to encourage continued reporting
Seaneke et al. 2023 ⁸⁰	Ghana	Cross-sectional study				The App is useful and user friendly. Concerns about the privacy and security of personal information.	Support raising awareness to enhance the acceptance and use the app by both healthcare professionals and patients
Showande et al. 2013 ⁸¹	Nigeria	Questionnaire survey				Pharmacovigilance is not included in the pharmacy curriculum. Lack of Knowledge. Pharmacy students need to be well grounded in pharmacovigilance activities to improve reporting.	The Pharmacist Council and University Commission to immediately implement the new curriculum which includes pharmacovigilance courses
Showande et al. 2022 ⁸²	Nigeria	mixed methods (questionnaire survey and observational study)				Some patients reported experiencing ADRs to healthcare professionals. Patients are unaware of the existence of Pharmacovigilance Rapid Alert System for Consumer Reports (PRASCOR). Poor Community pharmacists can identify ADRs. Poor documentation and reporting of the observed ADRs by community pharmacists.	
Udoeye et al. 2018 ⁸³	Nigeria	Cross-sectional survey				High awareness but attitude and practice through very poor. Availability of reporting forms to all pharmacists. Regular reminders during meetings and teachings, that reporting ADRs is ethical and mandatory.	
Yamoah et al. 2019 ⁸⁴	Ghana	Cross-sectional quantitative design				Awareness, lack of knowledge regarding and negative perceptions. Training and sensitization of healthcare professionals on AEFIs and vaccine safety. Pharmacovigilance and vaccine safety to be integrated in academic institutions.	
Yawson et al. 2022 ⁸⁵	Ghana	Cross-sectional survey				Good awareness and positive attitudes but low ADRs reporting. Healthcare managers and the regulator to pay attention to existing gaps in the knowledge of healthcare professionals in pharmacovigilance	



Table 2. Summary of findings by country on pharmacovigilance

Country	Number of Studies	Key Findings	Recommendations
Nigeria	36	Poor reporting and lack of information in PHC facilities, with trained community health extension workers more likely to report. Males report more than females. High incidence of ADRs related to antiretroviral drugs.	Implement standardized reporting and enhance training for healthcare professionals.
Ghana	17	Lack of structured drug safety systems, workload constraints, fear of blame and costs associated with reporting. Mobile phone reporting is effective, but forms are often unavailable.	Develop national ADR monitoring systems and integrate pharmacovigilance into academic curricula.
Burkina Faso	2	Underreporting of ADRs with current systems in development. Health and Demographic Surveillance System is useful for monitoring safety in rural areas.	Strengthen healthcare worker training and improve pharmacovigilance infrastructure.
Cote d'Ivoire	2	Underreporting of ADRs. Treatment modification is a feasible strategy for monitoring.	Training and mentoring healthcare professionals; feedback mechanisms to motivate reporting; collaboration with public health programs.
Senegal	1	Barriers in medication access affecting reporting. Need for supervision and community sensitization for ADR reporting.	Establish patient safety education and train community health professionals in reporting methods.
Sierra Leone	1	Pharmacovigilance systems currently in development with significant gaps in awareness and reporting capabilities.	Strengthening healthcare worker training to promote awareness and improve reporting practices.

National Pharmacovigilance Systems

The findings indicate that all West African countries included in this review have established national pharmacovigilance centers, with varying degrees of functionality:

- **Ghana** was the first country to join the WHO PIDM in 2001 and maintains a robust pharmacovigilance framework through the Food and Drugs Authority (FDA).
- **Nigeria** has a well-defined ADRs reporting system using the Yellow Card Scheme, supported by the National Agency for Food and Drug Administration and Control (NAFDAC).
- **Côte d'Ivoire** and **Burkina Faso** have recently formalized pharmacovigilance activities but face challenges in implementation and resource allocation.
- **Sierra Leone's** pharmacovigilance system, established in 2008, continues to develop under the WHO's guidance.

While WHO collaboration has strengthened reporting systems, resource constraints, including staffing and infrastructure, hinder full implementation across the region.

Adverse drug reaction Reporting Mechanisms and Challenges

ADRs reporting mechanisms varied across countries. Key findings include:

1. **Reporting Tools:** Manual reporting forms (e.g., Yellow Cards) remain the most widely used tools. However, underreporting remains a significant challenge, with healthcare professionals citing barriers such as:
 - **Lack of awareness and training** in ADRs reporting (reported in 60% of studies).
 - **Fear of litigation** or punitive consequences.
 - **Time constraints** due to workload pressures.
 - **Lack of feedback** after ADRs submission.



2. **Technological Integration:** Electronic ADRs reporting systems, such as Ghana's Med Safety App and Nigeria's pilot digital platforms, have shown promise but remain underutilized due to poor internet access and training gaps.

Stakeholder Involvement

Stakeholder collaboration is critical for successful pharmacovigilance systems. Findings revealed:

1. **Regulatory Bodies:** WHO and the UMC play a central role in guiding national pharmacovigilance activities.
2. **Healthcare Professionals:** Physicians, nurses, and pharmacists were identified as primary ADRs reporters, but underreporting was widespread.
3. **Patients:** Public awareness of ADRs reporting was low across all studies, highlighting the need for educational campaigns.

Challenges and Barriers

The primary challenges identified in the review include:

- **Resource Limitations:** Insufficient funding, inadequate staffing, and subpar infrastructure were prevalent across most studies. These financial constraints significantly hinder the capacity of regulatory bodies to perform essential functions, such as implementing training programs, executing awareness campaigns, and enhancing infrastructure. The scarcity of qualified human resources is a critical barrier to effective pharmacovigilance.
- **Knowledge Gaps:** A recurrent issue is the lack of pharmacovigilance training for healthcare professionals, coupled with the absence of pharmacovigilance education in academic curricula. This results in a noticeable deficiency in clinical knowledge and experience among healthcare practitioners concerning the completion of ADR reporting forms, ultimately leading to the underutilization of available reporting resources.

- **Communication Barriers:** Ineffective feedback mechanisms and low levels of awareness among patients further impede the reporting of ADRs.
- **Lack of Reporting Resources:** Reports from some primary healthcare centers (PHCs) highlighted the absence of necessary ADR reporting forms, which can severely obstruct data collection efforts.
- **Awareness Gaps:** A general lack of understanding regarding the importance of ADR reporting exists, with many PHC workers perceiving ADRs as minor or insignificant issues. This attitude contributes to a culture of underreporting.
- **Reluctance to Engage in ADR Reporting:** Female physicians often exhibit a reluctance to engage with key representatives from pharmaceutical companies on matters related to ADRs.

Discussion

This scoping review overviews pharmacovigilance systems and ADRs reporting systems in West Africa. While progress has been made in establishing national pharmacovigilance centers and aligning with WHO standards, gaps in implementation and functionality still need to be evident.

Establishing national pharmacovigilance systems marks a critical step forward for many West African countries. As the first sub-Saharan African country to join the WHO Programme for International Drug Monitoring, Ghana has set a precedent for the region,^{31,38,42} Nigeria, with its structured ADRs reporting mechanisms, has also demonstrated leadership in the development of pharmacovigilance infrastructure.^{43,48,67} However, disparities among countries persist, with some systems still in their infancy and constrained by resource limitations.^{15,16,76} These differences underscore the need for cross-country collaboration and knowledge sharing to build regional capacity.⁸⁶⁻⁸⁸

Despite these advancements, the review reveals several barriers to effective pharmacovigilance. Underreporting ADRs remains a significant challenge, driven by



workload pressures, limited awareness, and fear of punitive repercussions.^{16,31,32,38,44,45,49,53,54,56,62,67} Resource constraints, including inadequate funding and insufficient staffing, further hinder the ability of national pharmacovigilance centers to function optimally.^{15,16} Additionally, public awareness of pharmacovigilance is alarmingly low, reducing the likelihood of patient engagement in ADRs reporting.^{33,35,37,41,49} The lack of feedback mechanisms for reporters further compounds this issue, discouraging participation from healthcare professionals and patients alike.^{12,38,54,60,61,77-79}

Collaboration between stakeholders, including regulatory bodies, healthcare professionals, and international organizations, plays an important role in the success of pharmacovigilance systems. The involvement of the WHO and the Uppsala Monitoring Centre has provided critical support to member countries. This has enhanced the country's ability to monitor and respond to drug safety signals.^{12,20,34,38,43,56,57,67} Healthcare professionals are central to ADRs reporting efforts, yet their contributions are often limited by systemic inefficiencies. Engaging the public through educational campaigns and community-based initiatives could significantly improve awareness and reporting rates, fostering a culture of safety and accountability.^{34,37,39,48,50,59,64,66,74} The non engagement of pharmaceutical companies by female physicians aligns with documented patterns of passive behaviour observed in clinical settings, potentially undermining collaborative efforts to enhance drug safety.⁸⁹

The need for legislation specific to pharmacovigilance in most countries presents a significant implementation barrier.^{20,57} Policies incentivizing healthcare professionals to report ADRs are crucial to addressing the issues that deter participation.^{31,34,67,71} Establishing standardized procedures and strengthening policy frameworks to mandate ADRs reporting can help to address barriers to under-reporting of ADRs.^{42,69,83} Furthermore, integrating digital tools, such as electronic ADRs reporting platforms, offers an opportunity to simplify reporting processes and improve data collection,

provided that infrastructure and training gaps are addressed.^{12,31,35,38,76,80,82} For instance, the utilization of mobile phone alerts and the Pharmacovigilance Rapid Alert System for Consumer Reporting (PRASCOR) offers innovative methods to facilitate timely ADR reporting directly to national centers.³⁵ It is evident that as countries invest in technological advancements, the effectiveness of their pharmacovigilance systems can be significantly improved.

To enhance the capacity of frontline healthcare providers and advance pharmacovigilance activities, strategies such as simplified ADR reporting systems, effective monitoring, and supportive supervision are recommended.^{69,80,85} Additionally, incorporating ADR-related topics into the educational curricula of institutions training health professionals could increase awareness and improve reporting practices.^{37,70,84}

This scoping review highlights the need for targeted interventions to strengthen pharmacovigilance in West Africa. Continuous professional development programs for healthcare staff and public awareness campaigns can address knowledge gaps and improve ADRs reporting.^{35,46,58,69,79,82} Investment in technological infrastructure and robust feedback systems will further enhance the efficiency and impact of pharmacovigilance activities.^{35,80,31,36,41,60,63,75,78} By addressing these challenges, West African countries can build more resilient systems to ensure medication safety and protect public health.^{40,57,82}

Recommendations

- 1. Policy Development by Regulatory Bodies:** It is essential to strengthen legal frameworks that mandate ADR reporting and ensure accountability for both healthcare providers and pharmaceutical companies. This will help create a robust foundation for effective pharmacovigilance practices.
- 2. Protective Policies for Healthcare Professionals by the Ministry of Health:** The ministry should develop protective policies addressing the fears and concerns that healthcare providers have regarding

ADR reporting. These policies should aim to alleviate apprehensions related to punitive actions, thereby encouraging more healthcare professionals to report adverse reactions.

3. **Regular Training by the National Pharmacovigilance Centre:** There should be frequent training sessions for healthcare professionals that emphasize their ethical and legal responsibilities concerning ADR reporting. Such training will enhance their confidence and competence in identifying and reporting ADRs.
4. **Public Awareness Campaigns by the National Pharmacovigilance Centre:** Engaging the public through continuous educational initiatives is crucial. Awareness campaigns should focus on the significance of ADRs, the importance of reporting them, and the specific mechanisms available for reporting.
5. **Incorporating Pharmacovigilance into Education by Training Institutions:** Health-related academic curricula must integrate topics related to pharmacovigilance and ADR reporting. This initiative will help cultivate foundational knowledge among future healthcare professionals, preparing them for active roles in pharmacovigilance.
6. **Resource Allocation by the National Government:** Adequate resource allocation is fundamental. When healthcare professionals are equipped with the necessary tools and support, they can effectively prioritize and monitor patient safety across all regions.
7. **Technological Integration:** The use of mobile applications and electronic reporting tools should be promoted to streamline the ADR reporting process. Such technologies can facilitate quicker, more efficient reporting, making it easier for healthcare professionals and patients alike.
8. **Multi-Disciplinary Collaboration:** Strengthening pharmacovigilance systems requires collaboration among various stakeholders, including public health programs, non-governmental

organizations (NGOs), the National Pharmacovigilance Centre (NPC), health facilities, and healthcare professionals. A multidisciplinary approach is vital to leverage education, technology, and policy reforms to enhance pharmacovigilance efforts in the region.

Limitations of the study

Despite the valuable insights gained from this review, there are notable limitations to consider. First, the inclusion of only English-language studies may have excluded relevant literature from Francophone countries. This limitation could restrict the generalizability of our findings across the broader West African context.²⁸

Additionally, our reliance on publicly available data may have led to the omission of unpublished or grey literature, which could provide further context and insights into pharmacovigilance systems in the region.

Another significant limitation is the lack of diversity among the studies sourced from anglophone countries. This homogeneity may not fully capture the disparities and variations present across different anglophone contexts, potentially influencing the comprehensiveness of our conclusions.

Future research

Future research should focus on the integration of pharmacovigilance education into academic curricula to enhance the knowledge and skills of future healthcare professionals. Additionally, evaluating the effectiveness of public awareness campaigns on improving ADR reporting practices will provide valuable insights into their impact and inform best practices.

It is also crucial to investigate the role of faith-based organizations in strengthening pharmacovigilance systems, particularly in addressing the challenges posed by inadequate monitoring of drug safety. Longitudinal studies assessing the sustainability of pharmacovigilance reforms are essential to guide future strategies and ensure that improvements are maintained over time.



Furthermore, there exists a significant gap in the literature regarding traditional medicine in West Africa. Thus, research in this area is necessary to better understand the implications of traditional practices on pharmacovigilance and patient safety. Future studies should include qualitative methodologies, such as in-depth interviews, to enhance understanding and facilitate cross-country comparisons within the region.

By addressing these critical research areas, we can foster a more comprehensive approach to enhancing pharmacovigilance systems across West Africa.

Conclusion

In summary, the advancements in pharmacovigilance across West Africa indicate a strengthened commitment to ensuring drug safety; however, considerable challenges persist. Overcoming these obstacles will require targeted efforts in education, comprehensive policy reforms, and the integration of technological solutions to establish robust and sustainable pharmacovigilance systems.

By promoting collaboration among stakeholders and investing in capacity-building initiatives, West African nations can enhance health outcomes and create a safer healthcare environment for their populations. The establishment of effective ADR reporting channels, combined with continuous education and training programs, is crucial for building a resilient pharmacovigilance infrastructure that can tackle the unique challenges faced in the region.

With these strategic improvements in place, the framework for drug safety monitoring in West Africa is poised to evolve in line with global best practices, ultimately contributing to the health and well-being of its communities.

References

1. Uppsala Monitoring Centre. The use of the WHO-UMC system for standardized case causality assessment. Uppsala Monitoring Centre Uppsala. Accessed 15th March 2023. Available from: <https://www.who.int/publications/m/item/WHO-causality-assessment>
2. World Health Organization. World Health Organization [WHO]. The importance of pharmacovigilance. Geneva: World Health Organization. World Health Organization. Accessed 22nd March 2023. Available from: <https://www.who.int/publications/i/item/10665-42493>
3. Jeetu G, Anusha G. Pharmacovigilance: a worldwide master key for drug safety monitoring. *Journal of Young Pharmacists*. 2010;2(3):315-320. <https://doi.org/10.4103/0975-1483.66802>
4. Chen BK, Yang YT. Post-marketing surveillance of prescription drug safety: past, present, and future. *Journal of Legal Medicine*. 2013;34(2):193-213. <https://doi.org/10.1080/01947648.2013.800797>
5. Burke SP, Stratton K, Baciú A. The future of drug safety: promoting and protecting the health of the public. National Academies Press; 2007.
6. Al-Worafi YM. Drug safety in Palestine. In: *Drug safety in developing countries*. Academic Press, 2020; p. 471-80. <https://doi.org/10.1016/B978-0-12-819837-7.00034-0>
7. Rouveix B. Antibiotic safety assessment. *International Journal of Antimicrobial Agents*. 2003;21(3):215-221. [https://doi.org/10.1016/S0924-8579\(02\)00354-0](https://doi.org/10.1016/S0924-8579(02)00354-0)
8. Woosley RL, Whyte J, Mohamadi A, Romero K. Medical decision support systems and therapeutics: the role of autopilots. *Clinical Pharmacology & Therapeutics*. 2016;99(2):161-164. <https://doi.org/10.1002/cpt.259>
9. Antropova G, Okonenko T, Fikhtner O, Veber V, Nemyatykh O. Pharmacovigilance as a tool for ensuring economic security in the Russian healthcare system. Atlantis Press; 2021:68-73. <https://doi.org/10.2991/aebmr.k.210222.014>
10. Swathi B, Bhavika D, Begum N. Adverse drug reaction profiles of commonly used platinum compounds in cancer chemotherapy. *Int J Basic Clin Pharmacol*. 2015;4(2):284-289.
11. Pirmohamed M, Atuah KN, Dodoo AN, Winstanley P. Pharmacovigilance in developing countries. *British Medical Journal Publishing Group*; 2007. p. 462-462. <https://doi.org/10.1136/bmj.39323.586123.BE>



12. Mendoza YG, Jusot V, Adou F, et al. Enhancing Pharmacovigilance in Côte d'Ivoire: Impact of GSK's Training and Mentoring Pilot Project in the Abidjan Region. *Drug Saf.* 2024;47(2):147-159. <https://doi.org/10.1007/s40264-023-01368-3>
13. Mgboko CA. Impact of post marketing surveillance on falsified medicine in Nigeria. Innopharma Education. 2021. Available from: <https://repository.innoskills.com/items/493459f3-9e29-4017-872c-a12079859ef0>
14. World Health Organization. Summary of the evidence on patient safety: implications for research. World Health Organization; 22 Sept 2008. Available from: <https://www.who.int/publications/i/item/9789241596541>
15. Opadeyi AO, Fourrier-Réglat A, Isah AO. Assessment of the state of pharmacovigilance in the South-South zone of Nigeria using WHO pharmacovigilance indicators. *BMC Pharmacol Toxicol.* 2018;19(1):27. <https://doi.org/10.1186/s40360-018-0217-2>
16. Ejekam C, Fourrier-Réglat A, Isah A. Evaluation of pharmacovigilance activities in the national HIV/AIDS, malaria, and tuberculosis control programs using the World Health Organization pharmacovigilance indicators. *Sahel Med J.* 2020;23(4):226-235. https://doi.org/10.4103/smj.smj_46_19
17. Alomar M, Tawfiq AM, Hassan N, Palaian S. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. *Therapeutic Advances in Drug Safety.* 2020;11. <https://doi.org/10.1177/2042098620938595>
18. Chakraborty A, Venkatraman JV. Pharmacovigilance through phased clinical trials, post-marketing surveillance and ongoing life cycle safety. In: *The quintessence of basic and clinical research and scientific publishing.* Springer; 2023:427-442.
19. Zhou S-F, Ming Di Y, Chan E, et al. Clinical pharmacogenetics and potential application in personalized medicine. *Current drug metabolism.* 2008;9(8):738-784. <https://doi.org/10.2174/138920008786049302>
20. Abiri OT, Johnson WC. Pharmacovigilance systems in resource-limited settings: an evaluative case study of Sierra Leone. *Journal of Pharmaceutical Policy and Practice.* 2019;12:1-8. <https://doi.org/10.1186/s40545-019-0173-2>
21. Nagumo W-R. Pharmacovigilance and adverse drug reaction reporting practices among Ghanaian healthcare professionals. University of Sheffield; 2020.
22. Al-Worafi YM. Patient care related issues in the developing countries: drug related problems (DRPs). In: *Handbook of Medical and Health Sciences in Developing Countries: Education, Practice, and Research.* Springer; 2023:1-27.
23. Shafei L, Mekki L, Maklad E, et al. Factors that influence patient and public adverse drug reaction reporting: a systematic review using the theoretical domains framework. *International Journal of Clinical Pharmacy.* 2023;45(4):801-813. <https://doi.org/10.1007/s11096-023-01591-z>
24. Adenuga BA. Optimising adverse drug reactions reporting and strengthening of pharmacovigilance systems in Namibia. University of Namibia; 2021.
25. Cheng W, Du J, Chen C, et al. Exploring the influencing factors of adverse drug reaction reporting among medical personnel: a COM-B model-based study. *Journal of Pharmaceutical Policy and Practice.* 2024;17(1):2417410. <https://doi.org/10.1080/20523211.2024.2417410>
26. Maluleke TL. Development of a direct ADR reporting tool for patients to address under-reporting of ADRs to the National Pharmacovigilance Unit in South Africa. Stellenbosch: Stellenbosch University; 2022.
27. Costa C, Abeijon P, Rodrigues DA, Figueiras A, Herdeiro MT, Torre C. Factors associated with underreporting of adverse drug reactions by patients: a systematic review. *Int J Clin Pharm.* 2023 Dec;45(6):1349-1358. <https://doi.org/10.1007/s11096-023-01592-y>
28. Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. *Annals of internal medicine.* 2018;169(7):467-473. <https://doi.org/10.7326/M18-0850>
29. World Health Organization. WHO Programme for International Drug Monitoring. World Health Organization. Accessed 15th January 2023.



30. Onasanya SS, Yamoah P, Oosthuizen F. A Comparative Study of the Pharmacovigilance System in Nigeria and Ghana using WHO-Indicator Based Pharmacovigilance Assessment Tool.(IPAT). 2023. <https://doi.org/10.21203/rs.3.rs-2216812/v1>
31. Aborigo RA, Welaga P, Oduro A, et al. Optimising reporting of adverse events following immunisation by healthcare workers in Ghana: a qualitative study in four regions. *PLoS One*. 2022;17(12):e0277197. <https://doi.org/10.1371/journal.pone.0277197>
32. Acheampong F, Anto BP. Perceived barriers to pharmacist engagement in adverse drug event prevention activities in Ghana using semi-structured interview. *BMC Health Serv Res*. 2015;15(1):361. <https://doi.org/10.1186/s12913-015-1031-9>
33. Adediji WA, Adegoke AB, Fehintola FA. Adverse drug reactions reporting practice and associated factors among community health extension workers in public health facilities, Southwest, Nigeria. *Pan Afr Med J*. 2021;40:165. <https://doi.org/10.11604/pamj.2021.40.165.28574>
34. Adegbuyi TA, Fadare JO, Araromi EJ, et al. Assessment of Knowledge, Attitude and Practice of Adverse Drug Reaction Reporting Among Healthcare Professionals working in Primary, Secondary and Tertiary Healthcare Facilities in Ekiti State, South-West Nigeria. *Hospital Pharmacy*. Dec 2021;56(6):751-759. <https://doi.org/10.1177/0018578720957968>
35. Adisa R, Adeniyi OR, Fakeye TO. Knowledge, awareness, perception and reporting of experienced adverse drug reactions among outpatients in Nigeria. *Int J Clin Pharm*. Aug 2019;41(4):1062-1073. <https://doi.org/10.1007/s11096-019-00849-9>
36. Kukula VA, Doodoo AAN, Akpakli J, et al. Feasibility and cost of using mobile phones for capturing drug safety information in peri-urban settlement in Ghana: a prospective cohort study of patients with uncomplicated malaria. *Article. Malaria Journal*. 2015;14(1):411. <https://doi.org/10.1186/s12936-015-0932-8>
37. Adisa R, Omitogun TI. Awareness, knowledge, attitude and practice of adverse drug reaction reporting among health workers and patients in selected primary healthcare centres in Ibadan, southwestern Nigeria. *BMC Health Serv Res*. Dec 3, 2019;19(1):926. <https://doi.org/10.1186/s12913-019-4775-9>
38. Adu-Gyamfi PKT, Mensah KB, Ocansey J, et al. Assessment of knowledge, practices, and barriers to pharmacovigilance among nurses at a teaching hospital, Ghana: a cross-sectional study. *Article. BMC Nursing*. 2022;21(1):242. <https://doi.org/10.1186/s12912-022-00965-4>
39. Agu KA, Oparah AC, Ochei UM. Knowledge and attitudes of HIV-infected patients on antiretroviral therapy regarding adverse drug reactions (ADRs) in selected hospitals in Nigeria. *Perspectives in clinical research*. 2012;3(3):95-101. <https://doi.org/10.4103/2229-3485.100657>
40. Anyachebelu O, Aluh D. Pharmacists compliance to practice regulations and good professional practice: a case study of Nigerian community pharmacists. *Int J Pharm Pharm Sci*. 2018;10:98-104. <https://doi.org/10.22159/ijpps.2018v10i7.25858>
41. Appiah B, Poudyal A, Burdine JN, et al. Factors that influence the intention to use mobile phone caller tunes for patients reporting of adverse drug reactions: a qualitative study. *THERAPEUTIC ADVANCES IN DRUG SAFETY*. SEP 2019;102042098619871190. <https://doi.org/10.1177/2042098619871190>
42. Asiamah M, Akuffo KO, Nortey P, Donkor N, Danso-Appiah A. Spontaneous reporting of adverse drug reaction among health professionals in Ghana. *Archives of Public Health*. 20 Jan 2022;80(1):33. <https://doi.org/10.1186/s13690-021-00783-1>
43. Avong YK, Jatau B, Gurumnaan R, et al. Addressing the under-reporting of adverse drug reactions in public health programs controlling HIV/AIDS, Tuberculosis and Malaria: A prospective cohort study. *Article. PLoS ONE*. 2018;13(8):e0200810. <https://doi.org/10.1371/journal.pone.0200810>
44. Awodele O, Adeniran A, Awodele DF. Pharmacovigilance amongst patent medicine vendors (PMVs) in Ekiti state, Nigeria. *The International Journal of Risk & Safety in*



- Medicine. 2012;24(2):65-72. <https://doi.org/10.3233/JRS-2012-0562>
45. Awodele O, Akinyede A, Adeyemi OA, Awodele DF. Pharmacovigilance amongst doctors in private hospitals in Lagos West Senatorial District, Nigeria. *International Journal of Risk and Safety in Medicine*. 2011;23(4):217-226. <https://doi.org/10.3233/JRS-2011-0541>
 46. Awodele O, Daniel A, Popoola TD, Salami EF. A study on pharmacovigilance of herbal medicines in Lagos West Senatorial District, Nigeria. *The International journal of risk & safety in medicine*. 2013;25(4):205-217. <https://doi.org/10.3233/JRS-130604>
 47. Balogun SH, Adeleye OA. Patient reporting practices of suspected adverse drug reactions to antiretroviral drugs in a tertiary health facility in Nigeria. *The Nigerian postgraduate medical journal*. 2014;21(4):331-337. <https://doi.org/10.4103/1117-1936.163489>
 48. Balogun ST, Okon KO, Akanmu AO, Paul LM, Sodipo OA. Safety monitoring of herbal medicines in Nigeria: worrying state of pharmacovigilance system based on WHO core pharmacovigilance indicators. *Journal of Herbmmed Pharmacology*. 2021;10(2):202-208. <https://doi.org/10.34172/jhp.2021.22>
 49. Bello SO, Umar MT. Knowledge and attitudes of physicians relating to reporting of adverse drug reactions in Sokoto, north-western Nigeria. *Ann Afr Med*. Jan-Mar 2011;10(1):13-8. <https://doi.org/10.4103/1596-3519.76563>
 50. Chatio S, Aborigo R, Adongo PB, et al. Factors influencing adverse events reporting within the health care system: the case of artemisinin-based combination treatments in northern Ghana. *Malaria Journal*. 27 Feb 2016;15:125. <https://doi.org/10.1186/s12936-016-1172-2>
 51. Daniel A, Muhammad AS. Adverse drug reactions reporting among health professionals in government hospitals in Katsina State, Nigeria. *Texila International Journal of Public Health*. 2021;9(3) <https://doi.org/10.21522/TIJPH.2013.09.03.Art002>
 52. Eze SC, Odoh EC, Eze KC, et al. Assessment of pharmacovigilance activities among pharmacist interns in Nigeria: a cross-sectional study. *Future Journal of Pharmaceutical Sciences*. 8 Feb 2023;9(1)11. <https://doi.org/10.1186/s43094-023-00463-7>
 53. Fadare JO, Enwere OO, Afolabi A, Chedi B, Musa A. Knowledge, attitude and practice of adverse drug reaction reporting among healthcare workers in a tertiary centre in Northern Nigeria. *Tropical Journal of Pharmaceutical Research*. 2011;10(3) <https://doi.org/10.4314/tjpr.v10i3.4>
 54. Gidudu JF, Shaum A, Dodoo A, et al. Barriers to healthcare workers reporting adverse events following immunization in four regions of Ghana. *Article. Vaccine*. 2020;38(5):1009-1014. <https://doi.org/10.1016/j.vaccine.2019.11.050>
 55. Gulma KA. An exploratory study of seasonal malaria chemoprevention and pharmacovigilance for under-five children in Kebbi State, Nigeria. *Indian J Public Health*. Jul-Sep 2023;67(3):352-356. https://doi.org/10.4103/ijph.ijph_577_23
 56. Jaquet A, Djima MM, Coffie P, et al. Pharmacovigilance for antiretroviral drugs in Africa: lessons from a study in Abidjan, Cote d'Ivoire. *Pharmacoepidemiol Drug Saf*. Dec 2011;20(12):1303-10. <https://doi.org/10.1002/pds.2182>
 57. Kabore L, Millet P, Fofana S, Berdai D, Adam C, Haramburu F. Pharmacovigilance systems in developing countries: an evaluative case study in Burkina Faso. *Drug Safety*. May 2013;36(5):349-58. <https://doi.org/10.1007/s40264-013-0043-9>
 58. Mohammed LA, Aliyu AA, Maiha BB, Isa A. Knowledge, perception and reporting attitude of adverse effects following immunization among primary healthcare workers in sabon gari local government area Zaria, Kaduna State, Nigeria. *Article. Nigerian Journal of Basic and Clinical Sciences*. 2018;15(1):81-86. https://doi.org/10.4103/njbcs.njbcs_18_17
 59. Mohammed M, Umar FI, Labaran KS, et al. Evaluation of adverse drug reaction reporting among traditional medicine practitioners in zaria kaduna state nigeria. *Article. Tropical Journal of Natural Product Research*. 2019;3(3):85-90. <https://doi.org/10.26538/tjnpr/v3i3.4>



60. Ndiaye JLA, Diallo I, Ndiaye Y, et al. Evaluation of two strategies for community-based safety monitoring during seasonal malaria chemoprevention campaigns in Senegal, compared with the National Spontaneous Reporting System. *Pharmaceutical Medicine*. 2018;32(3):189-200. <https://doi.org/10.1007/s40290-018-0232-z>
61. Obieze A, Adigwe OP, Ibegbunam I, et al. Assessment of knowledge attitude and practice of pharmacovigilance by leaders in public health pharmaceutical supply chain in Nigeria. *Journal of Phytomedicine and Therapeutics*. 2022;21(2):910-921. <https://doi.org/10.4314/jopat.v21i2.13>
62. Ohaju-Obodo JO, Iribhogbe OI. Extent of pharmacovigilance among resident doctors in Edo and Lagos states of Nigeria. *Pharmacoepidemiol Drug Saf*. Feb 2010;19(2):191-5. <https://doi.org/10.1002/pds.1724>
63. Okezie EO, Fawole OI. Adverse drug reactions reporting by physicians in Ibadan, Nigeria. *Pharmacoepidemiology and Drug Safety*. May 2008;17(5):517-522. <https://doi.org/10.1002/pds.1597>
64. Omoleke SA, Getachew B, Isyaku A, et al. Understanding and experience of adverse event following immunization (AEFI) and its consequences among healthcare providers in Kebbi State, Nigeria: a qualitative study. *BMC Health Serv Res*. Jun 3, 2022;22(1):741. <https://doi.org/10.1186/s12913-022-08133-9>
65. Opadeyi AO, Fourrier-Réglat A, Isah AO. Educational intervention to improve the knowledge, attitude and practice of healthcare professionals regarding pharmacovigilance in South-South Nigeria. *Therapeutic Advances in Drug Safety*. 25 Jan 2019;10. <https://doi.org/10.1177/2042098618816279>
66. Oppong KG, Attakorah J, Enimil A, Ansah C, Buabeng KO. Antibiotic stewardship and its impact on antibiotic use at the child health directorate of a teaching hospital in Ghana. *African Journal of Applied Research*. 2022;8(2):322-331. <https://doi.org/10.26437/ajar.31.10.2022.22>
67. Oreagba IA, Ogunleye OJ, Olayemi SO. The knowledge, perceptions and practice of pharmacovigilance amongst community pharmacists in Lagos state, southwest Nigeria. *Pharmacoepidemiology and Drug Safety*. 2011;20(1):30-35. <https://doi.org/10.1002/pds.2021>
68. Osakwe A, Oreagba I, Adewunmi AJ, Adekoya A, Fajolu I. Impact of training on Nigerian healthcare professionals' knowledge and practice of pharmacovigilance. *The International journal of risk & safety in medicine*. 2013;25(4):219-227. <https://doi.org/10.3233/JRS-130605>
69. Osei JY, Nortey PA, Bando DA, Kenu E, Addo-Lartey AA. Adverse drug reaction reporting by community pharmacists in the Greater Accra Region of Ghana, 2016. *Ghana Med J*. Mar 2021;55(1):9-17. <https://doi.org/10.4314/gmj.v55i1.3>
70. Osemene KP, Afolabi MO. An evaluation of the knowledge and perceptions of pharmacy students on pharmacovigilance activities in Nigeria. Article. *BMC Research Notes*. 2017;10(1)273. <https://doi.org/10.1186/s13104-017-2586-9>
71. Osemene KP, Ayeni MI, Afolabi MO. The role of community pharmacists in monitoring adverse drug reactions in Nigeria. Article. *Journal of Pharmaceutical Health Services Research*. 2012;3(4):197-204. <https://doi.org/10.1111/j.1759-8893.2012.00100.x>
72. Oshikoya KA, Awobusuyi JO. Perceptions of doctors to adverse drug reaction reporting in a teaching hospital in Lagos, Nigeria. Article. *BMC Clinical Pharmacology*. 2009;914. <https://doi.org/10.1186/1472-6904-9-14>
73. Oshikoya KA, Senbanjo IO, Amole OO. Interns' knowledge of clinical pharmacology and therapeutics after undergraduate and on-going internship training in Nigeria: a pilot study. *BMC medical education*. 2009;9:50. <https://doi.org/10.1186/1472-6920-9-50>
74. Oshikoya KA, Senbanjo IO, Njokanma OF. Parental reporting of suspected adverse drug reactions in children in Lagos, Nigeria. *Arch Dis Child*. Jun 2009;94(6):469-73. <https://doi.org/10.1136/adc.2008.152629>
75. Powell JF, Henneh IT, Ekor M. Knowledge, attitude and practice of physicians and nurses at



- the cape coast teaching hospital in the Central Region of Ghana on spontaneous adverse drug reaction reporting. *PLOS ONE*. JUL 7, 2023;18(7):e0288100. <https://doi.org/10.1371/journal.pone.0288100>
76. Rouamba T, Sondo P, Derra K, et al. Optimal approach and strategies to strengthen pharmacovigilance in Sub-Saharan Africa: a cohort study of patients treated with first-line artemisinin-based combination therapies in the Nanoro Health and Demographic Surveillance System, Burkina Faso. *Drug Des Devel Ther*. 2020;14:1507-1521. <https://doi.org/10.2147/dddt.S224857>
 77. Sabblah GT, Akweongo P, Darko D, Dodoo AN, Sulley AM. Adverse drug reaction reporting by doctors in a developing country: a case study from Ghana. *Ghana medical journal*. 2014;48(4):189-193. <https://doi.org/10.4314/gmj.v48i4.4>
 78. Sabblah GT, Darko D, Härmark L, Van Puijenbroek E. Patient preferences and expectation for feedback on adverse drug reaction reports submitted in Ghana. *Article. Ghana Medical Journal*. 2019;53(2):150-155. <https://doi.org/10.4314/gmj.v53i2.10>
 79. Sabblah GT, Darko DM, Mogtari H, Härmark L, van Puijenbroek E. Patients' Perspectives on Adverse Drug Reaction Reporting in a Developing Country: A Case Study from Ghana. *Drug Saf*. Oct 2017;40(10):911-921. <https://doi.org/10.1007/s40264-017-0563-9>
 80. Seaneke SK, Darko DM, Nkansah E, et al. First results from the lessons learnt from the deployment of the Med Safety App for reporting adverse drug reactions in Ghana. *Digital Health*. 2023. <https://doi.org/10.1177/20552076231211276>
 81. Showande JS, Oyelola FT. The concept of adverse drug reaction reporting: awareness among pharmacy students in a Nigerian university. *Internet Journal of Medical Update*. 2013;8(1):24-30.
 82. Showande SJ, Ikuomola IF. Pharmacists' involvement with and pharmacy clients' awareness of adverse drug reaction reporting in Nigeria: a mixed-methods approach. *Journal of Pharmaceutical Health Services Research*. 30 Dec 2022;13(4):276-288. <https://doi.org/10.1093/jphsr/rmac032>
 83. Udoeye JA, Ozolua RI, Nwokike J. Assessment of the knowledge, attitude and practice of pharmacovigilance by pharmacists in two states in south-eastern Nigeria. *Tropical Journal of Pharmaceutical Research*. May 2018;17(5):937-945. <https://doi.org/10.4314/tjpr.v17i5.25>
 84. Yamoah P, Bangalee V, Oosthuizen F. Knowledge and perceptions of adverse events following immunization among healthcare professionals in Africa: a case study from Ghana. *Vaccines*. 2019;7(1):28. <https://doi.org/10.3390/vaccines7010028>
 85. Yawson AA, Abekah-Nkrumah G, Okai GA, Ofori CG. Awareness, knowledge, and attitude toward adverse drug reaction (ADR) reporting among healthcare professionals in Ghana. *Therapeutic Advances in Drug Safety*. 2022;13. <https://doi.org/10.1177/20420986221116468>
 86. van Puijenbroek E, Barry A, Khaemba C, et al. Short-term training: a useful approach for sustainable pharmacovigilance knowledge development in Tanzania, Kenya, Ethiopia and Rwanda. *Drug Safety*. 2024;47(12):1193-1202. <https://doi.org/10.1007/s40264-024-01469-7>
 87. World Health Organization. Western Pacific regional action agenda on regulatory strengthening, convergence and cooperation for medicines and the health workforce. World Health Organization. 30 April 2020. Accessed 20 February 2023. Available from: <https://www.who.int/publications/i/item/9789290618942>
 88. Al-Worafi YM, Ming LC. Healthcare systems in developing countries. In: *Handbook of medical and health sciences in developing countries: education, practice, and research*. Springer; 2024:1-22. https://doi.org/10.1007/978-3-030-74786-2_207-1
 89. Amanatullah ET, Morris MW. Negotiating gender roles: Gender differences in assertive negotiating are mediated by women's fear of backlash and attenuated when negotiating on behalf of others. *Journal of Personality and Social Psychology*. 2010;98(2):256. <https://doi.org/10.1037/a0017094>



Submitted 23 Jan 2025 , Revised 17 April 2025, Accepted 25 April 2025, Published August 2025

Conflicts of interest: None.

Cite this article as: Jalloh I, Bai James P, Thomas Abiri O, Wiafe E, Mensah K, Padayachee N. A scoping review of the pharmacovigilance systems in west African region. *Christ J Glob Health*. 2025 Aug; 12(2). <https://doi.org/10.15566/cjgh.v12i2.419>

© **Authors.** This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly cited. To view a copy of the license, visit <https://creativecommons.org/licenses/by/4.0/>

